Glaucoma is chronic, degenerative disorder that damages the eye's optic nerve, may result in vision loss and blindness. Factors such, high prevalence of glaucoma, technological advancement in diagnostic technique, rising treatment awareness are driving the market growth of glaucoma therapeutics globally.
The report titled “Glaucoma Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2023–2030” offers strategic insights into the overall glaucoma therapeutics market along with the market size and estimates for the duration 2020 to 2030. The research study covers in-depth analysis of market segments based on drug class and different geographical regions.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global glaucoma therapeutics market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global glaucoma therapeutics market. This report concludes with company profiles section that highlights major information about the key players engaged in global glaucoma therapeutics market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report.
Thus, the research study provides a holistic view of the global glaucoma therapeutics market, offering market size and estimates for the period from 2020 to 2030, keeping in mind the above-mentioned factors.
Glaucoma is a chronic, degenerative condition that damages the eye's optic nerve, resulting in vision loss and blindness. Factors such as increase in prevalence of eye disorders, significant unmet medical needs and rise in the incidence of age-related eye disorders are driving the market growth of glaucoma therapeutics globally. It is observed that in the year 2016, prostaglandin analogs was largest revenue generating segment because these are widely prescribed first-line treatments for glaucoma. Different studies indicated that fixed-dose combination such as Dorzolamide and Timolol, Latanoprost and Timolol, Brimonidine and Timolol are widely used in market. Patient adherence is more for fixed-dose combination as they reduces the risk of medication washout and also decrease daily topical preservative load. It is observed that beta blockers is second major revenue generating segment, they may be used alone or combined with other medications. They lower the pressure inside the eye and are generally used to treat open-angle glaucoma. Some adverse effects associated with the use of alpha-adrenergic agonists include increase in heart rate and blood pressure negatively impacting the growth of glaucoma therapeutic market.
In the base year 2021, North America dominated the glaucoma therapeutics market in terms of revenue and it is anticipated that it will show steady growth during forecast period of 2023-2030. Factors such as rising geriatric population, upsurge in funding by government agencies and private organizations in healthcare system, increasing incidence of eye disorders, improved diagnostic techniques drive the growth of glaucoma therapeutics market in North America. Europe is the second largest revenue generating regional market for glaucoma therapeutics. U.K., Germany and France are major revenue contributing countries in Europe. It is observed that Middle East and Africa is hold smallest market share and it is anticipated that it will show sluggish market growth during forecast period. Comparatively lower cost of treatment medication hinder the market growth of glaucoma therapeutics in Middle East and Africa. Currently, Asia Pacific is not a major revenue generating segment. However, it is anticipated that it will experience a significant growth during the forecast period. Factors such as increasing population, continuous economic development and developing healthcare infrastructure would contribute the market growth in Asia Pacific during forecast period.
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Glaucoma Therapeutics market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2022-2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Year | 2022 |
| Unit | USD Million |
| Segmentation | |
Drug Class
| |
|
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report
